Subscribe Now
 Already a subscriber? Log-in!
The monthly Laboratory Industry Report delivers expert perspective and trusted guidance on critical regulatory updates, operational and financial trends, plus trusted forecasts on the future of the diagnostic laboratory industry.
As a member of the Laboratory Industry Report community, you’ll take advantage of over 30 years of experience including:
- Expert strategies and advice on healthcare integration, capitation, lab technology and more
- Analysis of regulatory impact and relevant details on proposed legislation
- Comparative data on diagnostic lab test pricing and volumes
- Benchmarks to gauge your lab operations versus the diagnostic lab market at large
- Details on publicly-held labs, including executive earnings and performance
- Updates on industry mergers, acquisitions and alliances and large labs’ business activities
Laboratory Industry Report gives you direct access to industry experts to keep you current and informed on the latest issues affecting diagnostic laboratories across practice settings – hospital, commercial, group practice sites and network systems.
Clients find their membership to “LIR” to be much more than a news source; it’s where they to turn for business intelligence and exclusive insight on what's happening to key companies, how Wall Street views the industry, or the latest on mergers, buyouts, consolidations and alliances.
For over 30 years Laboratory Industry Report is a trusted resource for everyone with a vital stake in today's competitive diagnostic lab marketplace – from owners, directors, pathologists, CEOs, COOs, and CFOs to general managers, administrators, lab managers, and sales/marketing professionals.
As always Laboratory Industry Report, guarantees the accuracy, objectivity, and authority of its actionable
intelligence.
Gain a competitive edge for your diagnostic lab!
|
|
|
 |
 | LIR November 2008 (full PDF issue) |
| TOP OF THE NEWS
Execs remain positive despite stock turmoil
Avg. referral expense down for hospitals
SALARY ANALYSIS
Pathologists’ starting salaries between $100k-$250k
Nebraska lab cuts costs by paying more
INSIDE THE LAB INDUSTRY
Lab execs speak out on economy, lobbying priorities
Managed care orgs lose millions in Lehman, AIG exposure
INDUSTRY NEWSMAKERS
Response Genetics, NeoGenomics team up
Industry leaders launch OralDNA Labs
PHYSICIAN OFFICE LAB OUTLOOK
High error rates highlight lab’s role
FINANCIAL
Lab index fall 29% over 5 weeks
INDUSTRY BUZZ
FDA issues warning to LabCorp
Full Article |
| Hospital Referral Expense per Reportable Result Expected to Drop 11% by Year End |
| By the end of this year, the average referral expense per reportable result of sending a test to an outside reference laboratory is expected to fall to $32.84, down 11 percent from 2007’s figure of $36.98, according to analysis of hospital labs by the laboratory consulting firm Chi Solutions Inc. (Ann Arbor, Mich.). The median is expected to drop 12 percent from $33.30 in 2007 to $29.26 in 2008 (see Figure 1). Hospital labs currently dominate the $50 billion clinical lab market with 54 percent market share.
Full Article |
| Lab Stocks Level Out After October Plunge; Six Execs Offer Views on Latest Economic Developments |
| It was a rough October for the lab industry and the G-2 Laboratory Stock Index, which was down 29 percent over the past five weeks and 30 percent so far this year. But in the last two weeks the Index has leveled out, according to up-to-the-minute tracking of the Index available on www.g2reports.com.
Full Article |
| Survey Finds Many Starting Salaries for Pathologists Are Between $100k and $250k |
| Over 66 percent of starting salaries for pathologists are ranging between $100,000 to $250,000, according to the American Society for Clinical Pathology’s (ASCP) 2008 Resident Council Fellowship and Job Market Survey. Of the 121 respondents in 2008, 20 percent said they would be starting at under $100,000, 33 percent indicated they were receiving a starting salary in the range of $100,000 to $150,000, and another 33 percent said their starting salaries were between $150,000 and $250,000. Fourteen percent of the pathologists indicated they would be starting at a salary greater than $250,000 (see Figure 1). These salaries do not include benefits.
Full Article |
| Nebraska’s Pathology Services Saves $3k a Year by Paying Customer Service Reps More |
| Since Pathology Services, P.C.’s CEO David Glenn increased the hourly rate paid to customer service representatives in 2006 from $9 per hour to $12 per hour, he estimates he’s saved $3,000 a year. This has been realized primarily by decreasing turnover—at a monthly savings of approximately $1,000—as well as by improving efficiency, eliminating one-half of a full-time employee (FTE) at a savings of over $8,000.
Full Article |
| Inside the Lab Industry: Lab Execs See Economy Driving More Consolidation, Will Push New Administration for Higher Reimbursement |
| While Wall Street continues to find its footing following the recent infusion of $700 billion from the federal government, the current economic downturn is likely to further fuel consolidation in the lab industry, according to several CEOs and executives from both reference and esoteric labs who were recently interviewed by LIR. However, the tight credit market is likely to complicate the merger and acquisition (M&A) process.
Full Article |
| Response Genetics Teams With NeoGenomics to Expand Cancer Testing Sales Effort |
| Los Angeles-based Response Genetics wants to sell its lung and colorectal cancer tests beyond the West Coast market and is partnering with NeoGenomics Laboratories (Ft. Myers, Fla.) to develop a national sales strategy. NeoGenomics is a CLIA-certified lab that specializes in cancer genetic testing and offers testing services that include cytogenetics, flow cytometry, molecular diagnostics, and fluorescence in-situ hybridization–also known as FISH.
Full Article |
| Industry Veterans Plunge Into Dental Mol Dx Market With Launch of OralDNA Labs |
| Some former executives with American Esoteric Labs (AEL) and Lab One have joined forces to enter the dental molecular diagnostics market with the recent launch of Nashville-based OralDNA Labs. The initial menu will feature two saliva-based diagnostic panels—MyPerioPathsm and MyPerioIDsm—based on technology previously only available in Europe to target periodontal disease. The company plans on eventually expanding this menu to offer a broad offering of molecular, genetic, and other clinical tests.
Full Article |
| High Rates of Test Ordering, Reporting Errors in Physician Offices Highlight Role for Labs |
| In a recent study analyzing 590 event reports in physician offices (POLs), there were almost 1,000 testing errors, with almost 25 percent of these errors relating to reporting results to clinicians. Almost 13 percent of the 966 testing processing errors involved test ordering, while almost 18 percent were related to implementing the testing, including not performing the test at all, which was noted 6.7 percent in the study published in a recent issue of Quality and Safety in Health Care (2008;17;194-200).
Full Article |
| Lab Stocks Dip Sharply; Down 29% Over 5 Weeks, 30% for Year |
| The historic falls on Wall Street continued to impact the lab industry through late September and early October. For the week ended Oct. 17, 2008, the G-2 Laboratory Index was down 29 percent over the past five weeks and 30 percent so far in 2008. None of the 14 publicly traded labs tracked by the Index showed any growth over the past four weeks. In fact, all except one are down in the double digits compared to the previous four weeks. In addition, Nasdaq and S&P have yet to lift. The Nasdaq is down 36 percent, while the S&P 500 is down 36.38 percent so far in 2008.
Full Article |
| FDA Threatens LabCorp With Regulatory Action Over OvaSure Claims |
| The FDA’s concern over LabCorp’s marketing of its OvaSure ovarian cancer test appears to be intensifying. In a letter dated September 29, Steven Gutman, the FDA’s director of the Office of In Vitro Diagnostic Device Evaluation and Safety, warned CEO David P. King that the agency had conducted a review of the marketing and technical information available for the tests and concluded that there are "serious regulatory problems involving this device," and that regulatory action would be initiated if the premarket approval was not initiated to correct violations.
Full Article |
|
|
Please choose an archived issue to view newsletter table of contents above
|
|
